FibroBiologics is pursuing a development program for FSdC spheroids with the goal of advancing to clinical trials. The data includes comprehensive preclinical pharmacology and efficacy assessments ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics” or the 'Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and ...

FibroBiologics (FBLG) announced preclinical results for FSdC, an investigational FSdC spheroid-based therapy, demonstrating superior improvement ...

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti ...

Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

Experiments reveal that a time-dependent epistatic interaction influences how mice respond to opioids, and that intracellular fibroblast growth factors also influence opioid sensitivity.

This article is based on a poster originally authored by Fiona Leslie, Chloe Whiting, and Megan Webster. TGF-β1-mediated activation of fibroblasts, their transition to α-SMA-expressing myofibroblasts, ...